Quintiles Transitional Holdings (Q) has an average broker rating of 1.65, which is interpreted as a Buy, as rated by 13 equity analysts. Nonetheless, 8 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. 1 other analysts advise a Buy. Nevertheless, the majority of 4 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.
Quintiles Transitional Holdings (Q) has been rated by 10 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $83 and the lowest price target forecast is $62. The average forecast of all the analysts is $74.55 and the expected standard deviation is $6.2.
Quintiles Transitional Holdings (NYSE:Q): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $66.88 and $66.85 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $68.37. The buying momentum continued till the end and the stock did not give up its gains. It closed at $68.31, notching a gain of 1.61% for the day. The total traded volume was 1,851,527 . The stock had closed at $67.23 on the previous day.
Also, In the latest statement by the brokerage house, Wells Fargo downgrades its outlook on Quintiles Transitional Holdings (NYSE:Q). The current rating of the shares is Market Perform, according to the research report released by the firm. Previously, the company had a rating of Outperform. The rating by the firm was issued on May 12, 2016. The company shares have dropped -6.20% from its 1 Year high price. On Jul 29, 2015, the shares registered one year high at $80.45 and the one year low was seen on Feb 9, 2016. The 50-Day Moving Average price is $65.61 and the 200 Day Moving Average price is recorded at $65.48.
Quintiles Transnational Holdings Inc. is a biopharmaceutical services company. The Company is a provider of biopharmaceutical development services and commercial outsourcing services. The Company is engaged in the development and commercialization of pharmaceutical therapies. It also offers therapeutic, scientific and analytical services to its biopharmaceutical and other healthcare customers. The Company offers its services through two segments: Product Development and Integrated Healthcare Services. Its product development segment is a contract research organization (CRO) and is focused on Phase II-IV clinical trials and associated laboratory and analytical activities. Its Integrated Healthcare Services segment provides services, including commercial services, such as contract pharmaceutical sales forces, and healthcare business services, such as phase research, market access and consulting, and health information analytics and technology consulting.